*For demonstration purposes only

Since 1997, BioCheck, Inc. has been committed to the development and manufacturing of high-quality in vitro diagnostic test kits for the worldwide biomedical, pharmaceutical, and scientific research markets under cGMP and ISO 13485 standards. BioCheck is commercializing the MS-FAST analyzer (automated chemiluminescent immunoassay system) and associated Covid-19 test kits to allow convenient, instant, and accurate diagnosis of the disease with a bench top instrument. In addition, BioCheck also develops ultra-sensitive assays using Simoa™ technology (single molecule array), a powerful tool for detecting low-abundance biomarkers.